Ovarian Cancer

News alerts, weekly reports and conference planners

Related cancers:

‹

Ovarian Serous Adenocarcinoma (31)

›

FOLR1 positive	Ovarian Cancer	FOLR1 positive	Ovarian Cancer	mirvetuximab soravtansine-gynx Sensitive: A1 - Approval Immunogen Press Release - 5 days (New B) mirvetuximab soravtansine-gynx Sensitive : A1 Immunogen Press Release - 5d	mirvetuximab soravtansine-gynx Sensitive: A1 - Approval Immunogen Press Release - 5 days mirvetuximab soravtansine-gynx Sensitive : A1 Immunogen Press Release - 5 days - (New B)
BRCA2 mutation	Ovarian Cancer	BRCA2 mutation	Ovarian Cancer	IDE161 Sensitive: B - Late Trials IDEAYA Biosciences Press Release - 1 week (New B) IDE161 Sensitive : B IDEAYA Biosciences Press Release - 1wk	IDE161 Sensitive: B - Late Trials IDEAYA Biosciences Press Release - 1 week IDE161 Sensitive : B IDEAYA Biosciences Press Release - 1 week - (New B)
BRCA1 mutation	Ovarian Cancer	BRCA1 mutation	Ovarian Cancer	IDE161 Sensitive: B - Late Trials IDEAYA Biosciences Press Release - 1 week (New B) IDE161 Sensitive : B IDEAYA Biosciences Press Release - 1wk	IDE161 Sensitive: B - Late Trials IDEAYA Biosciences Press Release - 1 week IDE161 Sensitive : B IDEAYA Biosciences Press Release - 1 week - (New B)
FOLR1 overexpression	Ovarian Cancer	FOLR1 overexpression	Ovarian Cancer	mirvetuximab soravtansine-gynx Sensitive: B - Late Trials ESGO 2023 - 2 weeks (New B) mirvetuximab soravtansine-gynx Sensitive : B ESGO 2023 - 2wk	mirvetuximab soravtansine-gynx Sensitive: B - Late Trials ESGO 2023 - 2 weeks mirvetuximab soravtansine-gynx Sensitive : B ESGO 2023 - 2 weeks - (New B)
BRCA1 mutation	Ovarian Cancer	BRCA1 mutation	Ovarian Cancer	olaparib Sensitive: A1 - Approval ESGO 2023 - 2 weeks (New C3) olaparib Sensitive : A1 ESGO 2023 - 2wk	olaparib Sensitive: A1 - Approval ESGO 2023 - 2 weeks olaparib Sensitive : A1 ESGO 2023 - 2 weeks - (New C3)
BRCA2 mutation	Ovarian Cancer	BRCA2 mutation	Ovarian Cancer	olaparib Sensitive: A1 - Approval ESGO 2023 - 2 weeks (New C3) olaparib Sensitive : A1 ESGO 2023 - 2wk	olaparib Sensitive: A1 - Approval ESGO 2023 - 2 weeks olaparib Sensitive : A1 ESGO 2023 - 2 weeks - (New C3)
PD-L1 expression	Ovarian Cancer	PD-L1 expression	Ovarian Cancer	pembrolizumab Sensitive: C1 - Off-label ESGO 2023 - 2 weeks (New C4) pembrolizumab Sensitive : C1 ESGO 2023 - 2wk	pembrolizumab Sensitive: C1 - Off-label ESGO 2023 - 2 weeks pembrolizumab Sensitive : C1 ESGO 2023 - 2 weeks - (New C4)
ER positive	Ovarian Cancer	ER positive	Ovarian Cancer	CDK4 inhibitor + CDK6 inhibitor Sensitive: C3 – Early Trials ESGO 2023 - 2 weeks (New C3) CDK4 inhibitor + CDK6 inhibitor Sensitive : C3 ESGO 2023 - 2wk	CDK4 inhibitor + CDK6 inhibitor Sensitive: C3 – Early Trials ESGO 2023 - 2 weeks CDK4 inhibitor + CDK6 inhibitor Sensitive : C3 ESGO 2023 - 2 weeks - (New C3)
LOX overexpression	Ovarian Cancer	LOX overexpression	Ovarian Cancer	cisplatin Sensitive: D – Preclinical ESGO 2023 - 2 weeks (New D) cisplatin Sensitive : D ESGO 2023 - 2wk	cisplatin Sensitive: D – Preclinical ESGO 2023 - 2 weeks cisplatin Sensitive : D ESGO 2023 - 2 weeks - (New D)
LOX overexpression	Ovarian Cancer	LOX overexpression	Ovarian Cancer	paclitaxel Sensitive: D – Preclinical ESGO 2023 - 2 weeks (New D) paclitaxel Sensitive : D ESGO 2023 - 2wk	paclitaxel Sensitive: D – Preclinical ESGO 2023 - 2 weeks paclitaxel Sensitive : D ESGO 2023 - 2 weeks - (New D)
No biomarker	Ovarian Cancer	No biomarker	Ovarian Cancer	niraparib Sensitive: A1 - Approval niraparib Sensitive : A1	niraparib Sensitive: A1 - Approval niraparib Sensitive : A1
HRD	Ovarian Cancer	HRD	Ovarian Cancer	bevacizumab + olaparib Sensitive: A1 - Approval bevacizumab + olaparib Sensitive : C1	bevacizumab + olaparib Sensitive: A1 - Approval bevacizumab + olaparib Sensitive : C1
BRCA1 mutation	Ovarian Cancer	BRCA1 mutation	Ovarian Cancer	rucaparib Sensitive: A1 - Approval rucaparib Sensitive : A1	rucaparib Sensitive: A1 - Approval rucaparib Sensitive : A1
BRCA2 mutation	Ovarian Cancer	BRCA2 mutation	Ovarian Cancer	rucaparib Sensitive: A1 - Approval rucaparib Sensitive : A1	rucaparib Sensitive: A1 - Approval rucaparib Sensitive : A1
BRCA1 mutation	Ovarian Cancer	BRCA1 mutation	Ovarian Cancer	bevacizumab + olaparib Sensitive: A1 - Approval bevacizumab + olaparib Sensitive : C1	bevacizumab + olaparib Sensitive: A1 - Approval bevacizumab + olaparib Sensitive : C1
BRCA2 mutation	Ovarian Cancer	BRCA2 mutation	Ovarian Cancer	bevacizumab + olaparib Sensitive: A1 - Approval bevacizumab + olaparib Sensitive : C1	bevacizumab + olaparib Sensitive: A1 - Approval bevacizumab + olaparib Sensitive : C1
No biomarker	Ovarian Cancer	No biomarker	Ovarian Cancer	Aybintio (bevacizumab biosimilar) Sensitive: A1 - Approval Aybintio (bevacizumab biosimilar) Sensitive : A1	Aybintio (bevacizumab biosimilar) Sensitive: A1 - Approval Aybintio (bevacizumab biosimilar) Sensitive : A1
No biomarker	Ovarian Cancer	No biomarker	Ovarian Cancer	bevacizumab-awwb Sensitive: A1 - Approval bevacizumab-awwb Sensitive : A1	bevacizumab-awwb Sensitive: A1 - Approval bevacizumab-awwb Sensitive : A1
No biomarker	Ovarian Cancer	No biomarker	Ovarian Cancer	pegylated liposomal doxorubicin Sensitive: A1 - Approval pegylated liposomal doxorubicin Sensitive : A1	pegylated liposomal doxorubicin Sensitive: A1 - Approval pegylated liposomal doxorubicin Sensitive : A1
No biomarker	Ovarian Cancer	No biomarker	Ovarian Cancer	topotecan Sensitive: A1 - Approval topotecan Sensitive : A1	topotecan Sensitive: A1 - Approval topotecan Sensitive : A1
No biomarker	Ovarian Cancer	No biomarker	Ovarian Cancer	carboplatin + micellar paclitaxel Sensitive: A1 - Approval carboplatin + micellar paclitaxel Sensitive : A1	carboplatin + micellar paclitaxel Sensitive: A1 - Approval carboplatin + micellar paclitaxel Sensitive : A1
No biomarker	Ovarian Cancer	No biomarker	Ovarian Cancer	bevacizumab Sensitive: A1 - Approval bevacizumab Sensitive : A1	bevacizumab Sensitive: A1 - Approval bevacizumab Sensitive : A1
BRCA1 mutation	Ovarian Cancer	BRCA1 mutation	Ovarian Cancer	niraparib Sensitive: A1 - Approval niraparib Sensitive : A1	niraparib Sensitive: A1 - Approval niraparib Sensitive : A1
BRCA2 mutation	Ovarian Cancer	BRCA2 mutation	Ovarian Cancer	niraparib Sensitive: A1 - Approval niraparib Sensitive : A1	niraparib Sensitive: A1 - Approval niraparib Sensitive : A1
No biomarker	Ovarian Cancer	No biomarker	Ovarian Cancer	Aybintio (bevacizumab biosimilar) Sensitive: A1 - Approval Aybintio (bevacizumab biosimilar) Sensitive : A1	Aybintio (bevacizumab biosimilar) Sensitive: A1 - Approval Aybintio (bevacizumab biosimilar) Sensitive : A1
No biomarker	Ovarian Cancer	No biomarker	Ovarian Cancer	trabectedin Sensitive: A1 - Approval trabectedin Sensitive : A1	trabectedin Sensitive: A1 - Approval trabectedin Sensitive : A1
HRD	Ovarian Cancer	HRD	Ovarian Cancer	niraparib Sensitive: A1 - Approval niraparib Sensitive : A1	niraparib Sensitive: A1 - Approval niraparib Sensitive : A1
No biomarker	Ovarian Cancer	No biomarker	Ovarian Cancer	olaparib Sensitive: A1 - Approval olaparib Sensitive : A1	olaparib Sensitive: A1 - Approval olaparib Sensitive : A1
BRCA2 mutation	Ovarian Cancer	BRCA2 mutation	Ovarian Cancer	pamiparib Sensitive: A1 - Approval pamiparib Sensitive : A1	pamiparib Sensitive: A1 - Approval pamiparib Sensitive : A1
BRCA1 mutation	Ovarian Cancer	BRCA1 mutation	Ovarian Cancer	pamiparib Sensitive: A1 - Approval pamiparib Sensitive : A1	pamiparib Sensitive: A1 - Approval pamiparib Sensitive : A1
No biomarker	Ovarian Cancer	No biomarker	Ovarian Cancer	rucaparib Sensitive: A1 - Approval rucaparib Sensitive : A1	rucaparib Sensitive: A1 - Approval rucaparib Sensitive : A1
No biomarker	Ovarian Cancer	No biomarker	Ovarian Cancer	bevacizumab-bvzr Sensitive: A1 - Approval bevacizumab-bvzr Sensitive : A1	bevacizumab-bvzr Sensitive: A1 - Approval bevacizumab-bvzr Sensitive : A1
No biomarker	Ovarian Cancer	No biomarker	Ovarian Cancer	bevacizumab-maly Sensitive: A1 - Approval bevacizumab-maly Sensitive : A1	bevacizumab-maly Sensitive: A1 - Approval bevacizumab-maly Sensitive : A1
No biomarker	Ovarian Cancer	No biomarker	Ovarian Cancer	Krabeva (bevacizumab biosimilar) Sensitive: A1 - Approval Krabeva (bevacizumab biosimilar) Sensitive : A1	Krabeva (bevacizumab biosimilar) Sensitive: A1 - Approval Krabeva (bevacizumab biosimilar) Sensitive : A1
No biomarker	Ovarian Cancer	No biomarker	Ovarian Cancer	bevacizumab-adcd Sensitive: A1 - Approval bevacizumab-adcd Sensitive : A1	bevacizumab-adcd Sensitive: A1 - Approval bevacizumab-adcd Sensitive : A1
BRCA2 deletion	Ovarian Cancer	BRCA2 deletion	Ovarian Cancer	niraparib Sensitive: A1 - Approval niraparib Sensitive : A1	niraparib Sensitive: A1 - Approval niraparib Sensitive : A1
BRCA1 deletion	Ovarian Cancer	BRCA1 deletion	Ovarian Cancer	niraparib Sensitive: A1 - Approval niraparib Sensitive : A1	niraparib Sensitive: A1 - Approval niraparib Sensitive : A1
No biomarker	Ovarian Cancer	No biomarker	Ovarian Cancer	docetaxel Sensitive: A2 - Guideline docetaxel Sensitive : A2	docetaxel Sensitive: A2 - Guideline docetaxel Sensitive : A2
No biomarker	Ovarian Cancer	No biomarker	Ovarian Cancer	carboplatin + docetaxel Sensitive: A2 - Guideline carboplatin + docetaxel Sensitive : A2	carboplatin + docetaxel Sensitive: A2 - Guideline carboplatin + docetaxel Sensitive : A2
No biomarker	Ovarian Cancer	No biomarker	Ovarian Cancer	ifosfamide Sensitive: A2 - Guideline ifosfamide Sensitive : A2	ifosfamide Sensitive: A2 - Guideline ifosfamide Sensitive : A2
No biomarker	Ovarian Cancer	No biomarker	Ovarian Cancer	5-fluorouracil Sensitive: A2 - Guideline 5-fluorouracil Sensitive : A2	5-fluorouracil Sensitive: A2 - Guideline 5-fluorouracil Sensitive : A2
No biomarker	Ovarian Cancer	No biomarker	Ovarian Cancer	leucovorin calcium Sensitive: A2 - Guideline leucovorin calcium Sensitive : A2	leucovorin calcium Sensitive: A2 - Guideline leucovorin calcium Sensitive : A2

Ovarian Cancer

Associations(527)

Associations
(527)